generate human car cell express secondgeneration antimesothelin msln car intracellular cd3ζ domain either cd28 antimsln28z car 41bb antimsln41bbz car costimulatory domain fig s3 confirm ab928 effect different car design human system antimsln car cell cocultured suit2msln tumour cell presence absence neca serially titrate ab928 neca dampen ifnγ il2 release antimsln28z fig 6a antimsln41bbz fig 6b car cell interestingly ifnγ release affect neca lesser extent il2 ab928 turn restore cytokine release fig 6a b. thus ab928 block adenosine mediate suppression cytokine production human car cell independently car design analyse effect neca ab928 human antimsln28z car cell determine car cell phenotype flow cytometry perform rtcabased cytotoxicity assay ab928 restore activation dependent upregulation pd1 whereas tim3 lag3 cd45roccr7 expression influence neca ab928 fig 6c s4b neither neca ab928 modulate car cell cytotoxicity antimsln28z car cell fig s4a among aspect insufficient cell traffic tumour 53 54 antigen heterogeneity 46 immunosuppressive tme 49 major factor prevent treatment success car cell therapy broader range tumour 35 37. extracellular adenosine act soluble immune suppressant tme limit effective antitumour cell response 14. many strategy target adenosine axis develop investigate among others target adenosineproducing ectonucleotidases cd39 cd73 adenosine receptor a2r a2r improve efficacy immunotherapy conventional chemotherapy explore 5 6. blockade a2r bring forward strategy enhance car cell remain unclear coblockade a2r would yield similar better result effect would conserve across different car design present study impact a2r a2r antagonist ab928 efficacy different secondgeneration car cell assess describe extracellular adenosine specifically act dampen cell receptormediated signal 55. lack adequate cell stimulation partly responsible diminish effector function cell anergy generation presence high concentration adenosine 22. model murine antiepcam car cell cytokine secretion upregulation activation marker proliferation response antigendependent stimulation markedly impair presence adenosine analogue neca contrast addition ab928 lead improve ifnγ il2 tnfα secretion well restore upregulation pd1 tim3 cd25 cd69 response antigenstimulus indicate adequate cell activation beyond surrogate marker cell functionality critical importance ifnγ tnfα describe play critical role treatment success act solid tumour induce antitumour immunity bystander immune cell evoke antigenindependent destruction tumour stroma cell 56,57,58,59. similarly il2 promote cell proliferation effector function 60 61. consistently ab928 also reverse neca mediate inhibition cell proliferation observe ifnγ production cd4 cd8 car cell enhance presence ab928 find interest consider recent find highlight significant role play cd4 cell establish sustain antitumour immunity 61,62,63,64. effect pd1 tim3 expression line result giuffrida et al 21 contrast previously report data suggest adenosine signal enhance exhaustion anergy cell evidence upregulation checkpoint molecule 20 65. however experimental set chronic stimulation thus anergy exhaustion unlikely occur instead upregulation pd1 tim3 physiological consequence acute cell activation 66 67 consequence adenosinemediated inhibition cell activation marker associate activation reduce likewise reinstall upon inhibition adenosine signal previous study extensively characterise effect adenosine adoptively transfer cell 14 21 38. importantly genetic ablation adenosine receptor lead effectorlike phenotype enhance activation effector function car cell ultimately result better survival 21 38. find daily oral dose ab928 efficacious improve car cell activation promote effectorlike phenotype car cell tumour bear mouse confirm previous find demonstrate functionality adenosine receptor inhibitor car cell vivo set moreover ab928 also protect secondgeneration human antimsln28z antimsln41bbz car cell adenosinemediated suppression cytokine release note cell bear secondgeneration car different costimulatory motif antigen comparably suppress adenosine indicate neither cd28 41bb costimulatory domain overcome adenosinemediated effect effect adenosine direct car cell kill controversial masoumi et al observe reduce cytolytic function human car cell presence neca flow cytometrybased cytotoxicity assay 39. interestingly a2r knockdown sch58261 small molecule a2r antagonist protect car cell use rtca ass car cell kill observe impair cytotoxic function murine antiepcam car cell presence neca adenosine note ab928 protect car cell kill capacity inhibition highlight potential utility also call attention advantage dual target adenosine receptor might single target although work still require fully demonstrate observation contrast observe suppression human antimsln28z car cell cytotoxicity neca importantly line previously publish evidence beavis et al giuffrida et al report neca negligible impact murine human car cell cytotoxicity chromium release assay 21 38. thus seem adenosine hamper kill ability car cell certain set possibly strength car cell vitro however disregard possibility set longterm exposure adenosine cytotoxic potential car cell would suppress adenosine overall factor determine extend adenosine influence car cell cytotoxicity yet define cell highly sensitive adenosinemediated suppression giuffrida et al recently suggest genetic pharmacological target a2r prevent 50 adenosinemediated effect cell 21. a2r a2r activation lead signal via camppkacreb axis 51. show necainduced creb phosphorylation antiepcam car cell abrogate presence 1 08m ab928 result demonstrate ab928 effectively efficiently block immunosuppressive signal response adenosine importantly ab928 plasma level 1 08m higher feasible safe patient 27. find signal block cd4 cd8 car cell important previously show a2r a2r activation cd4 cell may promote generation 23 26. putatively cartransduced 68 could potentially boost adenosine ab928 present although would need formally demonstrate remain determine ab928 compare strategy target adenosine receptor overcome suppression adoptively transfer cell immunosuppressive effect adenosine cell primarily mediate predominantly express a2r make attractive target improve cellmediated antitumour immunity 20 21. small molecule a2r antagonist sch58261 38,39,40 cpi444 65 kw6002 69 well approach genetically target a2r shrna knockdown 38 39 crisprcas9mediated knockout 20 21 successfully use enhance act preclinical study however grow evidence suggest a2r also play important role adenosinemediated suppression antitumour response indirectly suppress cell function show a2r antagonism reduce differentiation suppressive capacity suppressive myeloid cell lead increase presence tumourinfiltrating cd8 cell vivo 23 25 26 70. recently chen et al show pharmacological a2r antagonism prior adoptive cell transfer improve treatment efficacy 71. among small molecule inhibitor target adenosine receptor ab928 first dual a2r a2r antagonist clinical development however yet formally prove advantage dual single target genetic target elegant way render car cell resistant one immunosuppressive factor 72. provide continuous protection suppression therefore allow single dose cell product however safety concern regard offtarget edit administration car cell permanent deletion immune checkpoint remain 72. small molecule inhibitor turn may suffer variable pharmacokinetics pk require repeat dose turn beneficial case unwanted serious adverse event 73. may also enable improve recruitment endogenous antitumour response act immune cell 74 75. combination therapy car cell cell intrinsic extrinsic icb already explore detail pd1 axis currently investigate clinical trial thus far unclear approach provide best result regard clinical outcome safety 76. ab928 currently evaluation phase 1 2 clinical trial test efficacy safety pk pharmacodynamics pd ab928based combination therapy tumour indication nct03846310 nct04262856 nct04381832 nct03720678 nct04660812 ab928 orally administer daily dose promise preliminary result result previous study suggest beneficial safety pk pd profile drug patient 27 29 30. overall ab928 reliably protect murine human car cell suppressive adenosinemediated effect observe study administer similarly regimen currently investigation clinical trial ab928 improve car cell activation vivo thus reason combination therapy ab928 high translational potential may promise approach enhance car cell efficacy however give fact limitation car cell therapy limit traffic tumour remain believe multimodal approach target one bottleneck car cell therapy necessary enable treatment broader range tumour recently find combine tumourdirected traffic expression dominantnegative receptor dnr shield car cell tgfβ immunosuppressive tme synergistically improve car cell efficacy solid tumour 45. similar approach combine tumourdirected recruitment protection immunosuppressive tme may also applicable combination therapy ab928 car cell \<SEP>0